Lung Cancer Screening
Customize your policy alerts
Sign up for Aetna Policy 0380 alerts
Get alerted when Policy 0380 changes without checking for updates manually.
Monitor payer policy activity
This policy governs coverage for annual low-dose computed tomography (LDCT) screening for lung cancer in specified high-risk current or former smokers, and lists tests considered experimental or investigational. It affects clinicians ordering screening and Aetna members meeting the criteria.
No material clinical or coverage changes in this revision.
Coverage Criteria for Lung Cancer Screening (LDCT)
Medical Necessity - Annual LDCT
Covered when ALL of the following are met
Annual LDCT (CPT 71271) is considered medically necessary when all conditions are met.
LDCT screening recommended population (guideline-derived)
Covered when ALL of the following are met (per guideline summaries in this extract):
Different organizations use slightly different age and pack‑year thresholds; consider patient comorbidity and suitability for curative treatment before screening.
Evidence-based screening stance
Summary of coverage-relevant evidence from included studies:
Supports coverage when selection criteria match trial populations; caution about harms (false positives, overdiagnosis, downstream invasive procedures) and need for program capability.
CAD for chest radiographs/CT
Findings on CAD performance and clinical utility:
Randomized data are insufficient to establish CAD chest radiography as an effective screening strategy; further RCTs needed.
PET in screening/evaluation
Role of PET:
Justification is recommended for PET use in evaluation of screening‑detected nodules; PET for primary population screening is not supported.
LDCT in asbestos-exposed individuals
Applicability and limitations:
Study limitations include pre‑screening selection bias and specialized multidisciplinary review pathways, limiting generalizability.
Screening with low-dose computed tomography (LDCT) for indications other than the defined high-risk smoking population (for example, routine LDCT screening in asbestos-exposed individuals) is considered experimental/investigational because effectiveness has not been established. The policy also lists computer-aided detection (CAD) for chest radiographs, positron emission tomography (PET) for primary screening, and artificial intelligence–based imaging for lung cancer screening as experimental/investigational and not covered for screening purposes. ICD-10 codes indicating active lung cancer or asbestos screening (e.g., C34.x, Z77.090) are not accepted indications for covered LDCT screening under this policy.
LDCT screening is not indicated for individuals who do not meet the age and smoking-history thresholds described by guideline bodies and this policy. Specifically, screening is not recommended for persons with fewer than the policy-specified pack-year history or those outside the recommended age ranges, for individuals who quit smoking more than 15 years ago (per prior guidance used in some guideline statements), or for those with severe comorbidities that would preclude potentially curative treatment. Clinicians should document smoking status, pack-year history, and years since quitting when assessing eligibility.
Routine chest radiography (CXR) and sputum cytology are not supported as effective lung cancer screening modalities for reducing lung cancer mortality. Systematic reviews and guideline statements have concluded that CXR and sputum cytology do not demonstrate a mortality benefit and therefore should not be used in place of LDCT for screening. Major professional organizations likewise do not recommend CXR or sputum cytology for routine screening.
Several evidence syntheses included in this policy restricted included studies to English-language publications and to developed-country settings and focused analyses on a limited set of non-traditional cardiovascular risk factors (ankle-brachial index, high-sensitivity C-reactive protein, and coronary artery calcium). As a result, other non-traditional risk factors and broader populations were excluded from those reviews, which limits generalizability of findings about cardiovascular risk prediction using LDCT-derived measures.
Use of CT screening outside the evidence-supported high-risk groups and outside investigational or research settings is not supported by conclusive data and therefore is not recommended. Prior studies have shown increased detection and treatment with CT screening without clear reductions in advanced cancer or mortality when applied beyond trial-like high-risk populations; until more definitive data are available, CT screening should be limited to those meeting established eligibility criteria or within studies designed to clarify benefit and harms.
Screening with chest x-ray (CXR) or sputum cytology as a routine method for lung cancer screening is not recommended and is considered not appropriate. Randomized trials and meta-analyses have not demonstrated that CXR or sputum cytology reduce lung cancer mortality compared with no screening, and guideline panels advise against their use for population screening.
Primary use of PET for lung cancer screening is not supported by the available evidence and is not established as medically necessary. Systematic reviews identified no trials demonstrating effectiveness of PET as a primary screening tool; selective PET for nodule characterization demonstrates relatively high sensitivity and specificity but may be overused and was often performed inappropriately for nodules smaller than 0.8 cm in some analyses. PET use for screening-detected nodules should be justified and generally reserved for appropriate diagnostic evaluation rather than routine primary screening.
Managing patients based on non-traditional risk factors identified on LDCT (for example, coronary artery calcium or other novel markers) has not been evaluated in prospective trials against traditional multivariable cardiovascular risk assessment. The clinical impact, downstream testing, and net benefit or harm of treatment strategies guided by these non-traditional factors remain unproven.
Billing and Coding
Provider-action / Billing guidance
Prior authorization/coverage: Annual low-dose CT (LDCT) for lung cancer screening (CPT 71271) is covered when the member meets the policy selection criteria (age 50–80 years, ≥20 pack-year smoking history, and if a former smoker, quit within 15 years). Counseling/shared decision-making visit (G0296) is covered for eligibility determination and shared decision making.
- Prior authorization: Providers should follow payer-specific prior-authorization workflows when required by the plan. When prior authorization is required, submit documentation supporting eligibility (age, detailed smoking history with pack-years calculation, quit date if applicable, and comorbidities affecting screening candidacy).
- Eligibility documentation and counseling: Document smoking history (current vs former, pack-years, quit date if former), shared decision-making discussion (benefits, harms, and alternatives), and that member meets selection criteria. Use G0296 for counseling/shared decision-making.
- Imaging modality prior-authorization expectations: LDCT (CPT 71271) is the covered modality for screening when criteria are met. PET and standard CT without LDCT protocol are not covered for screening indications.
- No explicit prior authorization in these excerpts: The policy text notes coverage criteria and use of G0296 but does not universally state a one-size-fits-all prior-authorization requirement; follow local plan rules.
- Denial triggers for non-covered codes/indications: Claims for PET (78811-78816) for screening, CT without LDCT protocol (71250), computer-aided detection (0174T/0175T), artificial-intelligence based screening, and chest x-ray for screening (71045-71048) are considered not covered for screening indications and may be denied.
- CXR not recommended for screening: Chest radiography (CXR) is not recommended or effective for lung cancer screening and is not covered for screening indications.
- Risks of inappropriate PET use: PET imaging for screen-detected small nodules may be overused and is frequently inappropriate for nodules <0.8 cm; inappropriate PET use can lead to excess costs and unnecessary procedures.
- Screening exclusion by risk/comorbidity: Document if screening is discontinued due to limited life expectancy or comorbidities that preclude curative treatment; such members are not appropriate candidates for LDCT screening.
- Evidence appraisal expectations: Providers may be asked to support medical necessity with documentation consistent with policy criteria and guideline-based evidence (USPSTF/NLST/ACCP/ACS as cited).
- No step therapy requirements described: This section contains no step therapy or quantity-limit policies.
- Administrative note: This section contains administrative and coding guidance; follow payer-specific billing, prior-authorization and documentation processes.
Provider Actions, Documentation, and Authorization
Confirm eligibility & perform shared decision‑making
Document and confirm that the patient meets guideline-based screening eligibility before ordering LDCT: age within recommended range and detailed smoking exposure. Clinicians should counsel patients about LDCT benefits, limitations, and potential harms as part of eligibility determination.
- Ascertain and record age and pack‑year history (per guidelines: e.g., USPSTF expanded to ages 50–80 and ≥20 pack‑years; some guidelines reference 55–74 and ≥30 pack‑years).
- Discuss benefits, limitations, false‑positive risk, and potential downstream testing prior to screening.
Expect justification for PET use in screening contexts
PET is not validated as a primary lung‑cancer screening test; selective PET for characterization of screen‑detected nodules may require justification because its role in screening is unclear and prior use in screening populations was variably appropriate.
- PET is a diagnostic tool and not established for primary screening; evidence does not support routine PET screening.
- Selective PET has high sensitivity/specificity for nodule evaluation but may require justification given uncertain appropriateness in screening contexts.
No explicit prior‑authorization requirements in evidence sections
The cited background evidence discusses screening modalities and diagnostic tools but does not impose explicit prior authorization rules for screening CT, coronary artery calcium assessment, or AI tools in these excerpts.
- These sections summarize evidence methods and conclusions; no specific payer prior‑authorization steps are specified here.
No additional prior‑authorization requirements listed
No prior authorization requirements are specified in these policy excerpts.
- Policy history and administrative sections do not add prior‑authorization steps.
(No action)
(No provider action specified in source excerpts.)
Exclude low‑risk or severely comorbid individuals from screening
Do not offer LDCT screening to individuals outside the policy’s high‑risk criteria (for example, those with insufficient pack‑years per prior guidance or with severe comorbidities that preclude potentially curative treatment); CT screening should not be performed in these cases.
- Individuals with <30 pack‑years (per older guidance) or those younger/older than guideline age ranges should not be screened outside investigational settings.
- Patients with severe comorbidities that would preclude curative treatment or limit life expectancy should not undergo CT screening.
(No action)
(No provider action specified in source excerpts.)
Step therapy not applicable
No step therapy (sequencing of treatments or tests required prior to authorization) is described in these excerpts.
- No step‑therapy requirements for imaging or screening are included in the cited material.
No authorization/step‑therapy policies present
No authorization or step‑therapy policies for imaging are described in the cited sections.
- Administrative/additional information sections do not introduce step‑therapy requirements.
Required documentation to support LDCT coverage
Maintain documentation showing the member meets LDCT selection criteria (age, pack‑year history, and quit date if a former smoker) and record that shared decision‑making (G0296) occurred when applicable.
- Record patient age and confirm it falls within the covered range (Aetna: 50–80 years).
- Document smoking history (pack‑years) and quit date if applicable.
- Retain documentation of counseling/shared decision‑making (G0296) used to determine eligibility.
Document detailed smoking history
Obtain and document a detailed smoking history: current vs former smoker, total pack‑years, and years since quitting to determine eligibility for LDCT screening.
- Record pack‑year calculation and whether the patient quit within the past 15 years if a former smoker.
- Use this documented history to inform the shared decision‑making discussion and eligibility determination.
Documentation expectations for asbestos‑exposed individuals
If considering LDCT for asbestos‑exposed individuals, document prior imaging and asbestos exposure history and note that LDCT utility in this population is not established; multidisciplinary review is recommended for indeterminate findings.
- Document prior chest imaging and standardized recording of asbestos‑related findings.
- Refer indeterminate nodules to multidisciplinary review per the asbestos‑exposed cohort practice described in the study.
Evidence appraisal and reporting expectations
Systematic reviews and meta‑analyses cited required standardized reporting and quality appraisal (for example, use of CHARMS, QUADAS‑2 and GRADE) to support evidence certainty and study inclusion.
- Evidence syntheses employed design‑specific criteria and appraisal tools (CHARMS, QUADAS‑2, GRADE).
- Providers contributing data or programs should expect standardized evidence reporting in referenced research.
Administrative notices — no documentation actions
(Administrative and copyright notices; no provider documentation actions specified in these excerpts.)
Denial triggers: non‑covered codes or indications
Claims for CPT/HCPCS or ICD‑10 codes that do not meet the policy selection criteria may be denied — examples include non‑covered CPT codes (71250, 71045–71048), PET CPT codes (78811–78816), CAD CPT codes (0174T/0175T), and ICD‑10 codes indicating active lung cancer or asbestos screening (e.g., C34.x, Z77.090).
Do not use chest x‑ray for lung cancer screening
Do not substitute chest x‑ray (CXR) for LDCT for lung cancer screening; CXR is not recommended for cancer screening and using CXR instead of LDCT would not align with guideline recommendations.
- Chest x‑ray screening is not recommended and is not supported as an effective screening modality compared with LDCT.
Avoid inappropriate PET use for screen‑detected nodules
PET was frequently used inappropriately for diagnostic evaluation of NLST screen‑positive patients; inappropriate PET use may lead to denials and increased costs — order PET only with appropriate justification (e.g., nodules ≥0.8 cm or radiology recommendation).
- NLST analysis found 21% of diagnostic PETs were inappropriate (performed for nodules <0.8 cm or without radiologist recommendation).
- Limit PET ordering to situations with radiologic justification or nodule size ≥0.8 cm to avoid inappropriate use.
(No action)
(No payer authorization or denial triggers specified in these excerpts.)
(No action)
(No authorization or denial triggers present in these sections.)
Background and Rationale
Lung cancer is frequently diagnosed at an advanced stage with poor long-term survival. Low-dose computed tomography (LDCT) is a reduced-radiation CT protocol developed to detect asymptomatic early lung cancers in high-risk individuals. Clinical trials and systematic reviews have shown that LDCT increases detection of early-stage cancers and, in trial-eligible high-risk smokers, can reduce lung cancer mortality compared with chest radiography; however, LDCT screening is associated with substantial rates of false positives, overdiagnosis, and downstream invasive procedures, and its benefits outside trial-like high-risk populations are uncertain.
Definitions and Abbreviations
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.